Dupixent Lawsuit 2026: MDL 3180 Is the Newest Federal Mass Tort — 38 CTCL Cases, No Settlement Yet & Who Qualifies
Direct answer: Federal Dupixent lawsuits were centralized in June 2026 into MDL No. 3180 — the newest major drug mass tort — before Judge Zahid N. Quraishi in the District of New Jersey. As of October 1, 2026, 38 cases were pending. The suits allege that Sanofi and Regeneron failed to warn that Dupixent may cause, accelerate, or worsen cutaneous T-cell lymphoma (CTCL), a blood cancer whose early symptoms can mimic eczema — the very condition the drug is prescribed to treat.
- Key fact 1: On June 4–5, 2026, the Judicial Panel on Multidistrict Litigation centralized all federal Dupixent CTCL cases into MDL No. 3180, In re: Dupixent (Dupilumab) Products Liability Litigation, in the District of New Jersey before Judge Zahid N. Quraishi.
- Key fact 2: The MDL began with 15 cases across 12 federal districts (14 transferred in, 7 more potential tag-alongs identified) and grew to 38 pending cases on the October 1, 2026 JPML report.
- Key fact 3: Judge Quraishi held the first MDL case-management conference on October 1, 2026, with a proposed initial management order due November 1, 2026.
- Key fact 4: On October 5, 2026, plaintiffs proposed 12 attorneys for MDL leadership — the team that will coordinate discovery, depositions, and motions toward eventual bellwether cases.
- Key fact 5: No settlement, no bellwether trial schedule, and no FDA label change have been announced; the FDA-approved prescribing information still does not mention T-cell lymphoma, though the FDA is evaluating whether regulatory action is needed.
What Dupixent is and who takes it
Dupixent (dupilumab) is an injectable biologic prescribed for eczema (atopic dermatitis), asthma, chronic rhinosinusitis with nasal polyps, prurigo nodularis, and — more recently — COPD and bullous pemphigoid. It works by blocking interleukin-4 and interleukin-13 signaling, calming the type-2 inflammation behind allergic and skin diseases. For patients whose eczema or asthma resisted everything else, it has been genuinely life-changing, which is why the allegations now emerging are so unsettling.
The cancer at the center of the cases
Cutaneous T-cell lymphoma (CTCL) is a rare blood cancer in which malignant T-lymphocytes migrate to the skin, causing rashes, plaques, and tumors; its two most common subtypes are mycosis fungoides and Sézary syndrome. Here is the cruel detail that defines this litigation: early CTCL can look and feel exactly like eczema — red, itchy, scaly patches. Patients and doctors alike can believe the drug is treating a flare-up while the cancer advances, which plaintiffs say delayed proper diagnosis and treatment by months or years.
The lawsuits allege that Sanofi, Regeneron Pharmaceuticals, and Genzyme Corporation failed to warn patients and physicians that Dupixent may cause, accelerate, or worsen CTCL; neglected to study its long-term cancer risks despite widespread use; and marketed it aggressively as safe while ignoring emerging safety signals. Whether the drug actually causes the disease — as opposed to unmasking a lymphoma that was already misdiagnosed as eczema — is the central scientific fight the MDL will resolve through expert evidence.
MDL 3180: the structure so far
When the Judicial Panel on Multidistrict Litigation created MDL 3180 on June 4, 2026, it found that the cases raised common questions about whether Dupixent may cause or accelerate CTCL, when the drug makers should have known about the risk, and whether adequate warnings were provided. The Panel assigned the litigation to the District of New Jersey — home to many of the defendants' operations — before Judge Zahid N. Quraishi. The Panel also left open the possibility that lawsuits involving other T-cell lymphomas, such as peripheral T-cell lymphoma (PTCL), could be added later through conditional transfer.
It is worth understanding what consolidation does and does not mean. An MDL is a case-management decision — it coordinates discovery and pretrial proceedings for efficiency. It is not a finding that the drug causes cancer, and each plaintiff will still have to prove their individual case. It is also not a class action: every claimant keeps their own lawsuit and their own recovery.
If you follow how new mass torts take shape, the pattern here will look familiar — early organization first, science second, settlement talk only much later. Compare the older, more mature hair-relaxer litigation and the Depo-Provera MDL to see how these dockets evolve over years.
The 2026 calendar: what just happened, what comes next
The MDL's organizational phase is moving fast. Judge Quraishi held the first case-management conference on October 1, 2026, after the parties submitted a joint management report addressing leadership, discovery, scheduling, and procedure. The parties are expected to submit a proposed initial management order by November 1. On October 5, 2026, plaintiffs proposed 12 attorneys to fill leadership positions — the lawyers who will coordinate discovery, depositions, and motions on behalf of all plaintiffs as the litigation moves toward the eventual selection of bellwether cases.
What has not happened is equally informative: no leadership appointments had been finalized, no bellwether trial schedule set, and no settlement announced as of mid-October 2026. Anyone who tells you there is a Dupixent settlement fund, a payout chart, or a claim deadline is selling you a story, not a fact.
Who qualifies to file
Firms reviewing Dupixent claims are looking for individuals who were prescribed Dupixent for eczema, asthma, COPD, bullous pemphigoid, or related conditions and were later diagnosed with cutaneous T-cell lymphoma — including mycosis fungoides or Sézary syndrome — or another qualifying T-cell lymphoma subtype. Families who lost a loved one to complications following a T-cell lymphoma diagnosis after Dupixent use are also being reviewed. The diagnosis itself matters enormously: lymphoma confirmed by skin biopsy and pathology is the foundation of every case in this docket.
The strongest files share a documented arc: Dupixent prescribed for a skin or respiratory condition, persistent or worsening "eczema" symptoms during treatment, and a later biopsy revealing CTCL. Records of dermatology visits, biopsy reports, oncology records, and the complete prescription history are the evidence attorneys will ask for first.
The deadline trap
This is the part that should not wait for the MDL to mature. Statutes of limitations vary by state and can be as short as one year — Tennessee's deadline, for example, is among the shortest in the country. Cancer cases raise discovery-rule questions: when did you know, or when should you have known, that the drug might be connected to the diagnosis? Those questions cut both ways, and courts resolve them case by case.
The honest posture is simple: the litigation is in its earliest organized phase, which is precisely the strategic window for new claimants to be evaluated — before leadership, discovery rulings, and bellwether selections define the field. Do not wait for settlement headlines; by the time they exist, filing windows may have closed.
For clear breakdowns of health and consumer topics like this one, see the Problem Solved channel on YouTube.
What honest lawyers will and will not tell you
An honest review will tell you four things: whether your diagnosis and prescription history fit the claims being filed, what records you need, what the deadline picture looks like in your state, and that no outcome can be promised — there is no settlement track record in this MDL yet, so compensation cannot be quantified today. Anything beyond that — especially dollar figures — is speculation, and you should treat it as such.
General information only — not legal or medical advice. If you were prescribed Dupixent, discuss your care with your doctor and your rights with a qualified attorney. Do not stop a prescribed medication without medical guidance.
Who Benefits From This — and Who Does Not
This article is for readers trying to tell whether a Dupixent claim is real, current, and worth a professional review — it separates the newest federal mass tort from the settlement rumors around it.
Who benefits:
- Patients prescribed Dupixent for eczema, asthma, COPD, bullous pemphigoid, or another approved use who were later diagnosed with CTCL (including mycosis fungoides or Sézary syndrome): the diagnosis, confirmed by biopsy, is what firms are reviewing. How to use this article: gather your prescription history and biopsy-confirmed diagnosis before seeking a review.
- Patients whose early CTCL was misdiagnosed as eczema for years while on Dupixent: this pattern sits at the core of the litigation, and the article explains why the discovery rule may matter for when the connection was reasonably knowable. How to use this article: note the timeline from first symptoms and eczema treatment to biopsy diagnosis.
- Readers who want the current status without hype: as of October 1, 2026, 38 cases were pending in MDL 3180 before Judge Zahid N. Quraishi in New Jersey, centralized June 4–5, 2026 — and there is no settlement yet. How to use this article: use the MDL number and case count to check any claim you are shown against this article.
Who does not benefit:
- Dupixent users without a CTCL or other qualifying T-cell lymphoma diagnosis: without that diagnosis there is no claim pattern described in this article.
- Anyone looking for a class-action signup or a settlement check: MDL 3180 is not a class action and not a settlement fund, and each plaintiff must prove their own case.
- Anyone expecting a dollar value for a claim: the article states plainly that no one can say — there is no settlement, no bellwether verdict, and no payout track record in this MDL.
Frequently asked questions
Is MDL 3180 a class action I can join?
No. MDL 3180 is a multidistrict litigation — a case-management procedure that coordinates discovery and pretrial work for individual lawsuits. It is not a class action, not a settlement fund, and not a finding that Dupixent causes cancer. Each plaintiff keeps their own case and must prove it.
I used Dupixent for asthma, not eczema. Can I still file?
Claims are being reviewed for patients prescribed Dupixent for any approved use — eczema, asthma, COPD, bullous pemphigoid, and others — who were later diagnosed with CTCL (including mycosis fungoides or Sézary syndrome) or another qualifying T-cell lymphoma. The diagnosis, confirmed by biopsy, is what matters.
My CTCL was misdiagnosed as eczema for years while I was on Dupixent. Does that matter?
That is one of the core patterns in this litigation — early CTCL mimics eczema, and plaintiffs allege the drug masked the cancer and delayed diagnosis. A biopsy-confirmed lymphoma diagnosis after Dupixent use is exactly what firms are reviewing, and the discovery rule may address when the connection was reasonably knowable.
How much could a Dupixent claim be worth?
Honest answer: no one can say. There is no settlement, no bellwether verdict, and no payout track record in this MDL — it was created in June 2026. Any dollar figure you see attached to Dupixent claims right now is speculation, not fact.
Who benefits most from this Dupixent article?
Patients prescribed Dupixent for an approved use who were later diagnosed with biopsy-confirmed CTCL, and families or readers trying to verify whether a Dupixent claim being advertised to them matches the real MDL 3180 status — 38 cases pending as of October 1, 2026, with no settlement yet.
How do I start a Dupixent claim review?
Collect your Dupixent prescription records and your biopsy-confirmed lymphoma diagnosis, write down the timeline from symptoms to diagnosis, and ask a qualified mass-tort attorney to review the case promptly — do not stop any prescribed treatment without talking to your doctor.